Sinovac Secures Exclusive Hepatitis A Vaccine Contract in Oman, Breaking Into GCC Market
Key Insights
Sinovac Biotech (search)'s inactivated hepatitis A vaccine Healive has won an exclusive public sector supply contract in Oman for 2026 and 2027, marking the company's first breakthrough in the Gulf Cooperation Council vaccine market.
The Chinese vaccine company achieved sole-supplier status after building a track record in product quality, delivery and logistics since beginning supply to Oman in 2022.
Healive remains the only Chinese hepatitis A vaccine to receive WHO prequalification, obtained in 2017, and provides at least 30 years of protection according to a 15-year follow-up study.
Sinovac Biotech (search) has secured an exclusive public sector supply contract for its inactivated hepatitis A vaccine in Oman for 2026 and 2027, representing the Chinese company's first major breakthrough in the Gulf Cooperation Council (GCC (search)) vaccine market. The deal marks a significant shift in a region that has traditionally sourced vaccines for national immunization programs from multinational pharmaceutical companies.
Market Entry and Recognition
The Chinese vaccine manufacturer's hepatitis A vaccine, Healive, was awarded sole-supplier status after the company began supplying the Oman market in 2022 and gradually built a track record in product quality, delivery and logistics. Sinovac described the Oman contract as demonstrating that its products and international supply capabilities have gained recognition in GCC (search) markets.
The GCC (search), a six-country bloc, applies strict regulatory and quality standards for vaccines, often aligned with those of the World Health Organization. WHO prequalification serves as a key requirement for market access in these markets.
Regulatory Achievement and Clinical Data
According to Sinovac, Healive received WHO prequalification in 2017 and remains the only Chinese hepatitis A vaccine to have obtained that status. This regulatory milestone has been crucial for the company's ability to compete in international markets with stringent quality requirements.
Oman incorporated the hepatitis A vaccine into its national immunization program in 2019, with children receiving two doses at 13 and 24 months of age. Sinovac cited a 15-year follow-up study showing the vaccine can provide at least 30 years of protection, demonstrating the long-term efficacy of the immunization.
Strategic Expansion
Sinovac characterized the deal as a key step in its expansion strategy for the Middle East and Africa regions. The contract represents a notable achievement for a Chinese vaccine manufacturer in penetrating markets traditionally dominated by established multinational pharmaceutical companies.
The exclusive nature of the contract for the 2026-2027 period indicates strong confidence from Omani health authorities in Sinovac's product quality and supply chain capabilities. This breakthrough could potentially open doors for the company in other GCC (search) member countries that maintain similar regulatory standards and procurement processes.